This study aims to see if a blood test, using a biomarker called miRNA-371, can accurately detect active testicular cancer. The study is observational, meaning doctors watch and collect data rather than giving treatment. If the blood test shows high miRNA-371 levels, patients may need surgery called RPLND (Retroperitoneal Lymph Node Dissection) to check for cancer. If miRNA-371 levels are normal, patients are watched closely and may have surgery later if levels go up.
- Participants must have had a type of surgery called radical inguinal orchiectomy.
- Blood tests and imaging like CT or MRI are required.
- Participants must be at least 18 years old and able to consent.
People cannot join if they have another type of cancer, are on other study drugs, or have uncontrolled illnesses. This study helps doctors understand if the biomarker miRNA-371 can find cancer early. It requires blood samples and possibly surgery. Participants need to be prepared for multiple hospital visits for tests and monitoring.